Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Removing the clock gene BMAL1 makes bacteria-engulfing defence cells in the body more effective, a new study from the Radcliffe Department of Medicine has found.

This is the first time a clock gene has been found to affect resistance to bacterial pneumonia, a fatal disease responsible for 5% of all deaths in the UK each year. (The main image depicts a a computer-generated image of a group of Gram-positive, Streptococcus pneumoniae bacteria, one of the bacteria types that cause the disease. Image credit: CDC PHIL). 

Most living things have an internal body clock which regulates when they sleep and when they wake up. A complex set of genes turning on and off, make this body clock run over roughly 24 hours, and a gene known by the acronym BMAL1 is one of the master regulators of this clock, controlling many other body clock genes and pathways.

Read more (Radcliffe Department of Medicine)

This research is also featured in a The Conversation article.

Similar stories

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.